A phase III randomised trial of 5 fraction prostate SBRT versus 5 fraction prostate and pelvic nodal SBRT
Trial summary:
PACE-NODES aims to compare prostate and pelvic nodal SBRT (PPN-SBRT) with prostate alone SBRT (P-SBRT) to determine whether PPN-SBRT has superior biochemical/clinical-failure free rate (reduces the risk of biochemical or clinical failure by 50% or more) than P-SBRT, in patients with high risk localised prostate cancer. 536 patients will be recruited from 25-30 UK and international sites over 2.5 years.
RT QA summary:
All QA activity will be streamlined with previous trial QA, where applicable. Please contact the RTTQA Group directly using the contact details below to discuss.
| QA Process | QA Activity | Required for Trial | Additional Details |
|---|---|---|---|
| Pre-Accrual | Facility Questionnaire |  | Streamlined |
| Outlining Benchmark Case | | Streamlined | |
| Planning Benchmark Case | | PPN-SBRT case | |
| Dummy Run | |||
| During Accrual | Individual Case Review | | 1 for each trial arm |
| Data collection | | All patients | |
| Dosimetry | | ||
| QA Streamlining | | PACE, PEARLS and PIVOTALboost trials |
RTTQA contact: pace-nodes.rtqa@nhs.net
Chief investigator: Professor Nicholas van As
Co-clinical leads: Dr Angela Pathmanathan and Professor Suneil Jain
Sponsor: The Institute of Cancer Research (pace-nodes-icrctsu@icr.ac.uk)
Funder: Prostate Cancer UK (PCUK)